ABBOTT INDIA LIMITED
🇮🇳India
- Country
- 🇮🇳India
- Ownership
- Private
- Established
- 1888-01-01
- Employees
- 73K
- Market Cap
- $7.5B
- Website
- http://www.abbott.com
A Comparison of Safety and Efficacy of Cefdinir Oral Suspension Versus Azithromycin in Pediatric Subjects With Acute Otitis Media
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2008-03-27
- Lead Sponsor
- Abbott
- Target Recruit Count
- 357
- Registration Number
- NCT00645112
A Comparison of the Safety and Efficacy of Cefdinir Oral Suspension Versus Amoxicillin/Clavulanate in Pediatric Subjects With Acute Otitis Media
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2008-03-27
- Lead Sponsor
- Abbott
- Target Recruit Count
- 425
- Registration Number
- NCT00644943
A Comparative, Single-Center, Pediatric Taste Test Study of Omnicef Versus Amoxicillin Antibiotic Suspension Medications
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2008-03-27
- Lead Sponsor
- Abbott
- Target Recruit Count
- 154
- Registration Number
- NCT00645125
Comparative Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Exacerbation of Chronic Bronchitis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2008-03-27
- Lead Sponsor
- Abbott
- Target Recruit Count
- 465
- Registration Number
- NCT00645086
Safety and Efficacy Study of Cefdinir Oral Suspension, in Pediatric Subjects to Treat Acute Otitis Media
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2008-03-27
- Lead Sponsor
- Abbott
- Target Recruit Count
- 447
- Registration Number
- NCT00645203
Pediatric Taste Test Study of Cefdinir (Omnicef) Versus Amoxicillin Antibiotic Suspension Medications
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2008-03-27
- Lead Sponsor
- Abbott
- Target Recruit Count
- 158
- Registration Number
- NCT00644891
Comparative Study of the Safety and Efficacy of Clarithromycin Extended-Release Tablets Versus Amoxicillin-Clavulanate for the Treatment of Acute Bacterial Sinusitis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2008-03-27
- Lead Sponsor
- Abbott
- Target Recruit Count
- 437
- Registration Number
- NCT00644553
Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-03-20
- Last Posted Date
- 2011-06-13
- Lead Sponsor
- Abbott
- Target Recruit Count
- 543
- Registration Number
- NCT00639158
A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Abbott
- Target Recruit Count
- 84
- Registration Number
- NCT00635817
- Locations
- 🇺🇸
Site Reference ID/Investigator# 8756, Los Angeles, California, United States
🇺🇸Site Reference ID/Investigator# 8755, San Diego, California, United States
🇺🇸Site Reference ID/Investigator# 8771, Gainesville, Florida, United States
Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2009-10-09
- Lead Sponsor
- Abbott
- Target Recruit Count
- 276
- Registration Number
- NCT00630877
© Copyright 2024. All Rights Reserved by MedPath